Authors:

Shijie Li

Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, People’s Republic of China

Abstract:

During the 2023 American Society of Clinical Oncology-Genitourinary (ASCO- GU) Cancers Symposium, a number of new and promising treatment options as well as clinical trials addressing castration-resistant prostate cancer (CRPC) were presented. 177Lu/111In-J591 and 225Ac-J591, two notable radionuclide drug conjugates (RDC), shown improved therapeutic efficacy in the treatment of patients with CRPC. Prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, protein kinase inhibitor (AKTi)-CAPltello-280, and dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab were additional promising treatment approaches for CRPC. We have compiled the most recent CRPC therapy approaches that were discussed at the ASCO-GU Cancers Symposium in 2023, as well as the most recent developments in CRPC clinical trials.

Keywords:

CRPC, RDC, Amphiphiles and retargeted proteins, CAR-T, AKTi

Citation:

Shijie Li. Clinical trials and new treatments for castration-resistant prostate cancer. World Journal of Medical Oncology 2023